Gina C. Wu
Senior Counsel | She/Her/Hers
Overview
Gina Wu is a skilled transactional lawyer who counsels life sciences clients in structuring, drafting, and negotiating domestic and cross-border transactions for the research and development of drug, medical device, gene therapy, cell therapy, and diagnostic products.
Career & Education
- Interim Corporate Counsel, Citrix Systems, Inc
- Member of the Securities and Corporate Finance Group, Vancouver-based firm
- McGill University, B.Com.
- University of British Columbia, J.D.
- Massachusetts
- Washington State
- Member, Washington State Bar Association
- Member, Boston Bar Association
- Member, American Bar Association
- Vice-Chair, Securities Law section, Canadian Bar Association, British Columbia branch (2013–2014)
- Treasurer and Secretary, Securities Law section, Canadian Bar Association, British Columbia branch (2012–2013)
Representative Matters
Licenses and Research Collaborations
- Represented not-for-profit client seeking to develop and commercialize treatments for rare disease in a license and research collaboration agreement opposite a prestigious research university.
- Represented an early-stage, venture-backed drug development client with complex gene coding product in connection with several in-licenses for patented manufacturing and delivery technologies.
- Drafted and negotiated sponsored research agreements with a leading pediatric hospital on behalf of venture-backed client with a gene editing product.
- Drafted and negotiated multiple evaluation and research and collaboration agreements with U.S. and ex-U.S. academic institutions to support development and validation of venture-backed client’s diagnostic device to detect molecular residual disease.
Manufacturing and Clinical Trials
- Drafted and negotiated various development and manufacturing agreements for GMP production of venture-backed client’s clinical-stage complex gene coding product.
- Drafted and negotiated development and GMP manufacturing agreement opposite a strategic partner for T-cell therapy drug products on behalf of clinical stage platform technology client.
- Advised a leading biopharmaceutical company formerly based in the United States as sponsor of various single-center and multi-center clinical trials, including a Phase 3 clinical trial involving approximately 520 subjects across sites located in the North America, Europe, and Asia.
- Oversaw contracting support for multiple clinical trials sponsored by a clinical-stage biopharmaceutical company developing transformative immunology-based therapies, including multinational Phase 3 trials involving sites in North America, South America, Europe, and Asia.